Erectile dysfunction is a common problem affecting up to 30 percent of men above 40 years old. Cardiovascular risk factors are closely associated with the development of vasculogenic erectile dysfunction. This explains the keen interest in identifying erectile dysfunction as a cardiovascular risk marker. A review of the literature reveals that erectile dysfunction has been shown to precede the development of coronary artery disease, and a number of hypotheses has been generated to support this association. Hence, it appears paramount that a complete assessment of erectile dysfunction would invariably involve assessment of cardiovascular risk factors and cardiac risk stratification. The Princeton III Consensus recommendation provides a straightforward guide for this purpose. The cardiologist should be involved early in the management of all patients with high cardiovascular risk, and some patients in the intermediate risk group.
INTRODUCTION
Erection is a complex phenomenon which involves a delicate and coordinated equilibrium among the neurological, vascular, and tissue compartments. It includes arterial dilation, trabecular smooth muscle relaxation, and activation of the corporeal veno-occlusive mechanism. Erectile dysfunction (ED) is de ned as the persistent inability to attain and maintain an erection su cient to permit satisfactory sexual performance. 1 e normal erection requires the autonomic nervous system activation of the parasympathetic system and inhibition of sympathetic activity. Nitric oxide (NO) released from the endothelium is the principal neurotransmitter mediating penile erection. Nitric oxide increases the production of cGMP, which in turn leads to relaxation of cavernous smooth muscle, and increased blood ow to the corpora cavernosa. e congested corpora cavernosa leads to compression of e erent veins, decreasing venous drainage. e signi cant increase of intracavernous pressure results in erections.
Erectile dysfunction is a common problem with a high prevalence and incidence worldwide. e prevalence worldwide is 16 percent in men aged 20 to 75 years old. e prevalence increases in older age; up to 35-40 percent in men older than 40 years old. 2 In Singapore, a population-based study involving 729 men more than 30 years old was conducted. Using the International Index of Erectile Dysfunction (IIEF) as a screening tool, up to 51 percent of men had some degree of erectile dysfunction, out of whom 23. 2 
PATHOPHYSIOLOGY OF ED AND THE RELATIONSHIP BETWEEN ED AND CAD
Men with ED commonly have underlying vasculogenic conditions which are risk factors for cardiovascular disease. Cardiovascular consequences of underlying conditions include endothelial dysfunction, impaired vasodilation, and development of atherosclerotic lesions. Arterial insu ciency and veno-occlusive dysfunction as a result of underlying conditions leads to reduced blood ow into the penis and excessive out ow, this in turn leads to ED. 4 (See Figure 1. ) In 2000, a subgroup analysis from the prospective random-sample cohort Massachusetts Male Aging Study (MMAS) involving 513 men with no erectile dysfunction, diabetes, or heart disease at baseline, showed prospective evidence that ED shares similar atherogenic risk factors with coronary artery disease (CAD), including active and passive smoking, overweight, hypertension, and diet. 5 One frequently quoted pathophysiologic mechanism used to explain the association between ED and CAD is the artery-size hypothesis. is hypothesis proposed a common pathophysiologic mechanism linking ED and CAD. Given the systematic nature of atherosclerosis, it could be hypothesised that all vascular beds might be a ected to the same extent, but the onset of symptoms might be related to the artery size. e size of penile arteries is smaller (1-2mm) compared with that of coronary arteries (3-4mm) , and the same level of endothelial dysfunction and atherosclerosis may lead to a more signi cant reduction of blood ow in erectile tissues compared with that in coronary arteries. Based on this hypothesis, ED a ecting penile arteries should usually precede CAD and its symptoms, including angina and myocardial infarction. 6 is hypothesis has been supported by a study published by JAMA in 2005. In this study, men aged 55 years old or older who were randomised to the placebo group (n=9457) in the Prostate Cancer Prevention Trial (PCPT) were evaluated 3-monthly for cardiovascular disease, ED and cardiovascular disease. Of these men, 8053 had no cardiovascular disease at study entry. After adjustment for important covariates including age, body mass index, blood pressure, serum lipids, diabetes, family history of myocardial infarction, race, smoking history, physical activity, and quality of life, incident ED was associated with a hazard ratio of 1.25 (95% CI:1.02-1.53, 0=0.04) for subsequent cardiovascular events during study follow-up. For men with either incident or prevalent ED, the hazard ratio was 1.45 (95% CI: 1.25-1.69; p<0.001). Noting that these ratios were in the range of risk associated with smoking or family history of myocardial infarction, the authors concluded that ED is a harbinger of cardiovascular clinical events in men. 7 Another possible association between ED and CAD is the role of in ammation. Low-grade subclinical in ammation a ects endothelial function and leads to a prothrombotic status. Studies have reported that ED onset and severity are associated with an increased expression of in ammatory markers. Vlachopoulos et al found that ED was related to an increased circulating level of these in ammatory markers in individuals with or without CAD, but no di erences were reported when comparing the circulating levels of pro-in ammatory markers between men with ED alone and those with CAD alone. us it was inferred that ED and CAD are equivalent in terms of in ammatory and pro-thrombotic activation, and that ED might confer such an incremental burden on top of CAD. 8 TESTOSTERONE DEFICIENCY SYNDROME LEADING TO CARDIOVASCULAR RISK FACTORS AND ED Testosterone de ciency syndrome (TDS) is also known as late-onset hypogonadism and andropause. TDS refers to the age-related decline in testosterone levels in ageing men, resulting in various clinical symptoms. As men age, the testes decline in function and testosterone secreted by them decreases. It has been reported that circulating testosterone concentration decreases by 0.4-2.0 percent yearly. is is due to a reduction in the function and size of the Leydig cells of the testes, as well as reduced amplitude of gonadotrophin secretion. In the USA, the crude prevalence of TDS in males aged at least 45 years old is estimated to be 38.7 percent, while in Asian countries, the reported prevalence of hypogonadism (de ned as total testosterone <11 nmol/l) was 18.2-19.1 percent. 9 TDS is increasingly recognised as a risk factor for the metabolic syndrome and its constituents including obesity, hypertension, dyslipidemia, and diabetes mellitus. Other than its association with chronic cardiovascular risk factors, low testosterone levels are also known to be an independent risk factor for mortality. In a study on male veterans, mortality in men with normal testosterone levels was 20.1 percent vs 24.6 percent in men with equivocal testosterone levels and 34.9 percent in men with low testosterone levels. After adjusting for age, medical morbidity, and other clinical covariates, low testosterone continued to be associated with increased mortality (hazard ratio, 1.88; 95% CI, 1.34-2.63, p<0.01), while equivocal testosterone levels were not signi cantly di erent from normal testosterone levels.
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At the same time, an adequate amount of testosterone is essential for the cascading mechanisms driving the penile erection response, including the production of nitric oxide synthase, release of nitric oxide, and augmentation of the synthesis of cGMP leading to arteriolar dilatation and relaxation of the corporeal smooth muscle. Hence it is highly likely that erectile dysfunction may be one of the presenting symptoms of testosterone de ciency. 11 e FRS is gender speci c, and the variables include age, total cholesterol, cigarette smoking, HDL cholesterol, and systolic blood pressure. 20 Having reviewed the above comprehensive list, the physician is advised to individualise the tests to the patient.
After the initial evaluation, exercise ability should be considered to estimate cardiovascular risk associated with sexual activity. Sexual activity is equivalent to walking 1 mile on the at in 20 min or briskly climbing 2 ights of stairs in 10 sec. Further evaluation using the exercise stress test is required for intermediate-risk patients. ese patients are then re-strati ed to low-or high-risk based on the results of stress testing. 19 Patients with known cardiovascular disease should be categorised to low, intermediate, and high risk. (See Table 1 .) e low-risk group consists of individuals for whom sexual activity does not represent a signi cant cardiovascular risk. e high-risk group consists of patients with cardiac conditions severe enough to lead to a signi cant risk related to sexual activity. ey should be referred to a cardiologist for further evaluation and receive intensive risk-factors treatment. Similar to patients with intermediate exercise ability, the intermediate cardiovascular risk group should undergo an exercise-stress test to re-stratify to lowor high-risk groups. 21 In all, the physician, urologist and cardiologist should collaborate closely to diagnose cardiovascular risk factors in patients presenting with ED, implement risk-factor lifestyle modi cation, and identify patients who would bene t from further cardiology assessment.
CONCLUSION
Erectile Dysfunction and CAD should be considered 2 di erent presentations of the same systemic disorder. e associations between the 2 conditions include cardiovascular risk factors, chronic in ammation and testosterone de ciency, leading to THE  EFFECTS  OF  TESTOSTERONE  REPLACEMENT  THERAPY  AND  CARDIOVASCULAR MORTALITY RISKS ere is a signi cant body of evidence showing that testosterone replacement therapy (TRT) can favourably modify cardiovascular risk factors, including a decrease in insulin resistance, waist circumference, and fat mass. Some studies have also shown that men with metabolic syndrome experience reversal of the features of the syndrome after testosterone replacement. 12 Two recent publications have raised concern that TRT increases cardiovascular risk.
ese studies were retrospective observational analyses and have been criticised, based on detailed epidemiologic and statistical analyses. ey have been reviewed by the US Food and Drug Administration (FDA) who concluded that, "each of the studies had major limitations, precluding the ability to draw de nitive conclusions". 13, 14 On the other hand, a meta-analysis in 2014 that included 75 randomised, placebo-controlled trials of testosterone treatment and evaluated the incidence of major adverse cardiovascular events, did not nd any association between testosterone therapy and actual cardiovascular events. 15 e above controversies led the US FDA to issue a statement in 2015 to state that healthcare professionals should prescribe testosterone therapy only for men with low testosterone levels caused by certain medical conditions and con rmed by laboratory tests; and that healthcare professionals should make patients aware of the possible increased cardiovascular risk when deciding whether to start or continue a patient on testosterone therapy. 16 In the meantime, the majority of international guidelines, including the European Association of Urology (EAU) guidelines on male hypogonadism, as well as the American Association of Clinical Endocrinologists (AACE) guidelines recommend that symptomatic men who have unequivocally low total and/or free testosterone levels con rmed on 2 separate occasions on samples drawn before 10 am, be considered for TRT after fully counselling the patient about the expected bene ts and side-e ects of the treatment. Patients should be assessed for cardiovascular risk factors before commencing TRT, and secondary prevention in men with pre-existing cardiovascular disease must be optimised.
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CARDIOVASCULAR SCREENING AS PART OF ED MANAGEMENT
e ird Princeton Consensus Conference discussed the role of cardiovascular disease screening in ED patients according to cardiovascular risks. For organic ED patients with no previous cardiovascular disease, the panel recommends they be considered at increased risk for cardiovascular disease. e evaluation should include (1) patient history, including age, traditional cardiovascular risk factors, and lifestyle; (2) physical examination, noting blood pressure, waist circumference, BMI, fundal arterial changes, cardiac auscultation, carotid bruits, and palpation of femoral and pedal pulses; (3) ED severity score and 
